Free Trial

Artivion (NYSE:AORT) Lowered to Neutral Rating by LADENBURG THALM/SH SH

Artivion logo with Medical background

Key Points

  • Artivion (NYSE:AORT) was downgraded from a "buy" to a "neutral" rating by LADENBURG THALM/SH SH, with a target price of $38.80, indicating a potential downside of 11.23% from its current price.
  • Despite the downgrade, various analysts remain bullish, with six analysts rating it as a buy and a consensus buy rating, alongside an average price target of $39.80.
  • The company reported $0.24 earnings per share in its last quarterly results, surpassing estimates and showing a year-over-year revenue increase of 15.3%.
  • Need better tools to track Artivion? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Artivion (NYSE:AORT - Get Free Report) was downgraded by investment analysts at LADENBURG THALM/SH SH from a "buy" rating to a "neutral" rating in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. They currently have a $38.80 price objective on the stock, up from their previous price objective of $32.00. LADENBURG THALM/SH SH's price target indicates a potential downside of 11.40% from the stock's current price.

AORT has been the subject of several other research reports. Oppenheimer reiterated an "outperform" rating on shares of Artivion in a research note on Friday, August 8th. Needham & Company LLC reiterated a "buy" rating and issued a $45.00 price objective (up previously from $32.00) on shares of Artivion in a research note on Friday, August 8th. Stifel Nicolaus increased their price objective on shares of Artivion from $36.00 to $40.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Canaccord Genuity Group raised their price target on shares of Artivion from $35.00 to $41.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Finally, Wall Street Zen upgraded shares of Artivion from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $39.80.

View Our Latest Analysis on AORT

Artivion Trading Down 0.1%

NYSE:AORT opened at $43.79 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -104.26 and a beta of 1.64. Artivion has a 52 week low of $21.97 and a 52 week high of $43.97. The firm has a 50-day moving average price of $31.67 and a two-hundred day moving average price of $28.29.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.11 by $0.13. The firm had revenue of $112.97 million during the quarter, compared to analyst estimates of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business's revenue for the quarter was up 15.3% on a year-over-year basis. On average, equities analysts expect that Artivion will post 0.37 earnings per share for the current fiscal year.

Insider Transactions at Artivion

In related news, Director Anthony B. Semedo sold 2,600 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $28.47, for a total value of $74,022.00. Following the completion of the transaction, the director directly owned 33,059 shares of the company's stock, valued at approximately $941,189.73. This trade represents a 7.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jean F. Holloway sold 8,748 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $29.00, for a total transaction of $253,692.00. Following the completion of the transaction, the senior vice president directly owned 178,510 shares of the company's stock, valued at approximately $5,176,790. This trade represents a 4.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 62,406 shares of company stock worth $1,801,262 in the last quarter. Insiders own 7.60% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AORT. LPL Financial LLC boosted its holdings in Artivion by 10.9% in the 4th quarter. LPL Financial LLC now owns 19,623 shares of the company's stock valued at $561,000 after purchasing an additional 1,925 shares during the period. JPMorgan Chase & Co. boosted its holdings in Artivion by 64.2% in the 4th quarter. JPMorgan Chase & Co. now owns 160,796 shares of the company's stock valued at $4,597,000 after purchasing an additional 62,893 shares during the period. Franklin Resources Inc. boosted its holdings in Artivion by 2.8% in the 4th quarter. Franklin Resources Inc. now owns 21,707 shares of the company's stock valued at $621,000 after purchasing an additional 600 shares during the period. Wells Fargo & Company MN boosted its holdings in Artivion by 22.1% in the 4th quarter. Wells Fargo & Company MN now owns 34,823 shares of the company's stock valued at $996,000 after purchasing an additional 6,299 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in Artivion by 13.1% in the 4th quarter. Russell Investments Group Ltd. now owns 144,360 shares of the company's stock valued at $4,127,000 after purchasing an additional 16,720 shares during the period. 86.37% of the stock is owned by institutional investors.

About Artivion

(Get Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Featured Stories

Analyst Recommendations for Artivion (NYSE:AORT)

Should You Invest $1,000 in Artivion Right Now?

Before you consider Artivion, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.

While Artivion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines